The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer

BJU International

Volumn 105, Issue SUPPL. 2, 2010, Pages 2-7

  Bunce, Colin ^a   Ayres, Benjamin E ^b   Griffiths, T R Leyshon ^c   Mostafid, Hugh ^c   Kelly, John ^d   Persad, Raj ^e   Kockelbergh, Roger ^f  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b FRIMLEY PARK HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

^d BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

BLADDER CANCER; BLADDER SURGERY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTOSCOPY; ECONOMIC ASPECT; FOLLOW UP; HUMAN; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW;

AMINOLEVULINIC ACID; CYSTOSCOPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PHOTOSENSITIZING AGENTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 75149141785     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09150.x     Document Type: Review

References (41)

1. Grasso M. Bladder cancer: a major public health issue. Eur Urol Suppl 2008 7: 510 515
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 18: 581 592 (Pubitemid 46359643)
3. Cancer Research UK. UK Bladder Cancer Statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/bladder/?a=5441. Accessed November 2009
4. Cancer Research UK. Bladder Cancer Survival Statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/bladder/#survival. Accessed November 2009
5. Oosterlinck W, van der Meijden A, Sylvester R et al. Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. Arnhem: European Association of Urology, 2009
6. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997 158: 62 7
7. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000 27: 1 13, vii
8. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982 127: 250 252
9. Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2007 101: 566 569
10. Babjuk M, Oosterlinck W, Sylvester R et al. Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. Arnhem: European Association of Urology, 2009. Available at: http://www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/ TaT1-BC.pdf. Accessed November 2009
11. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 130: 1083 1086
12. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 1980 46: 1158 1163
13. See WA, Chapman WH. Tumor cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. J Urol 1987 137: 1266 1269
14. Schulze M, Stotz N, Rassweiler J. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach. J Endourol 2007 21: 1533 1541
15. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001 165: 1121 1123
16. Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002 168: 475 478
17. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002 168: 67 71
18. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003 170: 433 437
19. Herr HW, Donat SM. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006 97: 1194 1198
20. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006 97: 1199 1201
21. Thomas K, O'Brien T. Improving transurethral resection of bladder tumour: the gold standard for diagnosis and treatment of bladder tumours. Eur Urol Suppl 2008 7: 524 528
22. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004 171: 135 138
23. Grossman HB, Gomella L, Fradet Y et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007 178: 62 7
24. Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007 178: 68 73 (Pubitemid 46908730)
25. Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005 174: 862 866
26. Jichlinski P, Guillou L, Karlsen SJ et al. Hexylaminolevulinate fluorescence cystoscopy. new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 2003 170: 226 229
27. Soloway MS, Murphy W, Rao MK, Cox C. Serial multiple-site biopsies in patients with bladder cancer. J Urol 1978 120: 57 9
28. Wiener HG, Vooijs GP, van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993 37: 163 169
29. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005 96: 798 802
30. Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005 174: 2129 2133
31. Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007 69: 675 679
32. Stenzl AS, Poessler WR, Fradet YF et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study. 24th Annual EAU Congress (Abstract) 2009
33. Scottish Intercollegiate Guidelines Network. Management of Transitional Cell Carcinoma of the Bladder: A National Guideline (Number 85). 2005. Available at: http://www.sign.ac.uk/pdf/sign85.pdf. Accessed November 2009
34. Zaak D, Wieland WF, Stief CG, Burger M. Routine use of photodynamic diagnosis of bladder cancer: practical and economic issues. Eur Urol Suppl 2008 7: 536 541
35. Mowatt G, N'Dow J, Zhu S et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy. 24th Annual EAU Congress (Abstract) 2009
36. Ray RR, Thomas K, Ajayi L et al. The true value of Hexvix photodynamic diagnosis following intravesical bacille Calmette Guerin treatment for superficial bladder cancer. AUA Annual Meeting (Abstract and poster) 2007
37. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 1999 52: 77 81 (Pubitemid 29016618)
38. GE Healthcare. Hexvix (hexylaminolevulinate) Summary of Product Characteristics
39. Vale L, Mowatt G, Kilonzo M, Zhu S, N'Dow J, Griffiths TR. Economic evaluation of photodynamic diagnosis and urinary biomarkers for detection and follow-up of bladder cancer. BJU Int 2009 103 (Suppl. 4 34. Abstract 74
40. Mowatt G, Zhu S, Kilonzo M et al. Systematic review of the clinical and cost-effectiveness of photodynamic diagnosis and urinary biomarkers (FISH, Immunocyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2009 13: 1 95
41. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003 21: 1315 30